Renal osteodystrophy

Renal osteodystrophy is a metabolic bone disorder arising from chronic kidney disease (CKD) and its attendant derangements in calcium, phosphate, vitamin D, and parathyroid hormone (PTH) metabolism.[1][2] It represents the bone-specific component of the broader systemic syndrome termed CKD-mineral and bone disorder (CKD-MBD).[2] In the jaws, the condition manifests as a spectrum of changes ranging from subtle loss of lamina dura and generalized demineralization to expansile ground-glass opacification and discrete brown tumors.[3][4][5] The pathogenesis centers on diminished renal 1α-hydroxylation of vitamin D, leading to impaired intestinal calcium absorption, chronic hypocalcemia, and compensatory secondary hyperparathyroidism; sustained PTH elevation drives accelerated osteoclastic resorption and disordered bone remodeling.[1][6] The mandible and maxilla are among the most commonly affected skeletal sites.[4][5] Management is primarily medical, directed at the underlying metabolic disturbance, with parathyroidectomy reserved for refractory hyperparathyroidism.[7]

KDIGO recommends restricting the term renal osteodystrophy to the histologically defined bone pathology of CKD, classified by the TMV system (turnover, mineralization, volume).[2] The encompassing systemic syndrome—including biochemical abnormalities, bone disease, and extraskeletal calcification—is designated CKD-mineral and bone disorder (CKD-MBD).[2]

• Osteitis fibrosa (cystica) describes the high-turnover histologic pattern driven by secondary hyperparathyroidism and is the subtype most relevant to jaw manifestations.[1][4]
• Brown tumor of hyperparathyroidism refers to focal, well-defined osteolytic lesions that develop within the spectrum of osteitis fibrosa.[4][8]
• Uremic leontiasis ossea is an older term for diffuse hyperostotic expansion of the facial bones in advanced disease.[9]
• Sagliker syndrome designates an extreme phenotype of CKD-related secondary hyperparathyroidism featuring severe craniofacial deformity, short stature, dental anomalies, and neuropsychiatric impairment.[10][11]
• The previously used umbrella term "renal osteodystrophy" for the entire metabolic syndrome is now considered obsolete in favor of CKD-MBD.[2]

CKD-MBD is nearly universal in advanced CKD, but clinically significant oral and maxillofacial manifestations are uncommon; an estimated 0.3–0.7% of CKD patients develop brown tumors or osteodystrophic jaw lesions.[3] In a multicenter series of 21 patients with oral/maxillofacial CKD-MBD, the mean age was 32.7 years, with a slight female predominance.[4] The mandible is the most frequently affected jaw site, followed by the maxilla.[4] Jaw involvement may occur at any CKD stage but is most pronounced in patients with end-stage renal disease on hemodialysis who have inadequately controlled secondary hyperparathyroidism.[7][11] Sagliker syndrome has been reported predominantly in developing countries where delayed or suboptimal treatment of secondary hyperparathyroidism is more common.[11]

Presentation and symptoms

• Facial and jaw swelling is the most common presenting complaint; bilateral buccal and palatal expansion of the maxilla and mandible produces progressive macrognathia.[3][4][5]
• Swelling is typically bony-hard, covered by intact, normal-appearing mucosa.[3]
• Pain is variable; diffuse bone pain may be present, but many patients are asymptomatic from the jaw lesions themselves.[4][5]
• Tooth mobility and spontaneous tooth loss can occur in advanced disease due to loss of alveolar support.[5][12]

Examination findings

• Generalized gingival pallor related to uremic anemia is common.[5]
• Intraoral soft-tissue masses may develop in severe cases, representing expansile brown tumors or reactive fibrous tissue.[11]
• Teeth may show altered eruption patterns, enamel hypoplasia, or pulp calcifications in patients with childhood-onset CKD.[13][14]

Tempo and complications

The condition evolves over months to years, paralleling the duration and severity of uncontrolled hyperparathyroidism.[15] Complications include pathologic fracture of the weakened jaw, progressive facial disfigurement (particularly in Sagliker syndrome), dental malocclusion, and airway compromise from severe maxillary expansion.[10][11] Periapical radiolucencies may mimic endodontic pathology, leading to unnecessary root canal treatment if the metabolic etiology is not recognized.[16]

Red flags

Rapid jaw expansion, markedly elevated PTH (often >800 pg/mL), and concurrent soft-tissue or vascular calcifications should prompt urgent nephrology and endocrine consultation.[4][7]

Radiographic alterations of the jaws are among the earliest detectable signs of renal bone disease and may precede clinical symptoms.[5]

Location and distribution

• Changes are characteristically bilateral and generalized, affecting both the maxilla and mandible.[3][4]
• The mandible is the most commonly involved jaw, with the body and ramus most frequently affected.[4]
• Brown tumors, when present, show a predilection for the mandibular body and symphysis, followed by the maxilla.[4][9]

Effects on the lamina dura and periodontal ligament space

• Loss of lamina dura is one of the earliest and most characteristic radiographic findings, reflecting generalized subperiosteal and endosteal resorption driven by PTH excess.[5][12][16]
• Widening of the periodontal ligament space commonly accompanies lamina dura loss and may be diffuse.[14][16]
• These changes are not pathognomonic—they also occur in other metabolic bone diseases—but their bilateral, generalized distribution in a patient with known CKD is highly suggestive.[5]

Internal architecture

• Generalized demineralization produces decreased trabecular density and increased radiolucency of the medullary bone.[12][17]
• Progressive loss of normal trabecular pattern may result in a homogeneous, ground-glass appearance, particularly in advanced osteitis fibrosa with reactive bone formation.[3][4]
• Alternating areas of radiolucency and sclerosis can create a coarsened, mottled trabecular pattern.[17][18]
• In the calvarium, the analogous finding is the classic "salt-and-pepper" skull pattern of granular mottling with loss of distinction between inner and outer tables.[18]

Periphery and shape

• Diffuse osteitis fibrosa/renal osteodystrophy produces ill-defined, poorly demarcated changes that blend into surrounding bone without a distinct border.[4]
• Brown tumors, in contrast, appear as well-defined, uni- or multilocular radiolucencies, occasionally with a thin sclerotic rim.[4][8]

Cortical involvement and expansion

• Thinning of cortical bone is common, detectable as reduced mandibular cortical width at the inferior border.[3][14][17]
• The mandibular cortical index frequently shows increased porosity or frank erosion in CKD patients compared with controls.[14][17]
• Advanced disease produces marked buccal and lingual cortical expansion of both jaws, which may be appreciated on cross-sectional imaging as diffuse, symmetric enlargement with preserved but thinned cortices.[3][9]
• Maxillary expansion can obliterate the maxillary sinuses.[9]

Effects on teeth and adjacent structures

• Periapical radiolucencies around vital teeth are a recognized finding that can mimic periapical pathology of endodontic origin; pulp vitality testing is essential to avoid misdiagnosis.[16]
• Tooth displacement and altered eruption may occur in areas of expansile disease.[3][13]
• Root resorption is occasionally observed but is not a dominant feature.[5]
• The inferior alveolar nerve canal may be displaced or obscured by surrounding bone changes.[3]

Soft-tissue and vascular calcifications

• Dystrophic and metastatic calcifications of the soft tissues are a recognized component of CKD-MBD and may be visible on panoramic radiographs or CBCT as calcified foci in the cheeks, parotid glands, or cervical vasculature.[9][14][19]
• Carotid artery calcifications (Mönckeberg medial arteriosclerosis) may be incidentally detected on panoramic radiographs in CKD patients.[19]

Recognized variants

• Brown tumor pattern: one or more well-defined radiolucent lesions, occasionally multilocular, within a background of generalized osseous changes.[4][8]
• Diffuse osteosclerotic pattern: uncommon; areas of increased bone density without discrete mass formation.[12]
• Uremic leontiasis ossea: diffuse hyperostotic expansion predominantly of the maxilla with sinus obliteration, representing an extreme form.[9]

Medical CT

On CT, brown tumors appear as expansile lesions of mixed lytic and sclerotic density; the relative proportions of solid, cystic, and hemorrhagic components determine attenuation.[9][20] Diffuse osteitis fibrosa manifests as generalized hyperostosis with ground-glass density replacement of normal trabecular architecture.[9] Uremic leontiasis ossea shows diffuse maxillary hyperostosis with anterior protrusion and complete sinus obliteration.[9] Dystrophic soft-tissue calcifications (parotid, cheek) are readily identified.[9]

MRI

Brown tumors are characteristically hypointense on T1-weighted images and of mixed signal intensity on T2-weighted images, with intense contrast enhancement reflecting their vascular fibrous stroma.[9][20] Fluid-fluid levels may be present when hemorrhagic or cystic components predominate.[20] In uremic leontiasis ossea, the expanded bone shows diffuse low T1 and T2 signal with scattered small hyperintense foci on T2.[9] MRI is most useful for evaluating soft-tissue extension and distinguishing brown tumors from aggressive neoplasms.

The differential diagnosis depends on the dominant radiographic pattern. Diffuse ground-glass changes require distinction from other fibro-osseous lesions, while focal radiolucencies must be separated from odontogenic and giant-cell–containing lesions. Correlation with medical history (known CKD), serum biochemistry (PTH, calcium, phosphorus, creatinine, alkaline phosphatase), and biopsy when indicated are essential for definitive diagnosis.[3][4][5]

The highest-risk diagnostic pitfall is misidentifying the periapical radiolucencies of renal osteodystrophy as endodontic disease, leading to unnecessary and potentially harmful dental procedures in a medically compromised patient.[16] When multiple periapical radiolucencies are encountered in a patient with known or suspected CKD, pulp vitality testing and serum PTH measurement should precede any endodontic intervention.[5][16]

The histologic hallmark of the high-turnover form (osteitis fibrosa) is marrow fibrosis with replacement of normal hematopoietic marrow by cellular fibrocollagenous connective tissue containing plump mesenchymal/fibroblast-like cells.[1][3] Key microscopic features include:

• Irregular woven (nonlamellar) bone trabeculae with prominent osteoblastic rimming, reflecting accelerated but disordered bone formation.[1][3]
• Aggregates of osteoclast-type multinucleated giant cells along resorption surfaces, indicating increased bone turnover.[1][3]
• Hemorrhage and hemosiderin deposition within the fibrous stroma, which imparts the brown coloration to focal lesions (brown tumors).[3][8]
• Increased osteoid seams may be present, reflecting the high rate of bone formation that does not keep pace with mineralization.[1]

Radiologic-pathologic correlation

The ground-glass radiographic appearance corresponds to the replacement of normal lamellar bone by woven bone and fibrous tissue.[1][3] Well-defined radiolucent brown tumors correspond to focal accumulations of giant cells, hemorrhage, and fibrous tissue with minimal mineralized bone.[4][8] The histologic appearance is indistinguishable from central giant cell granuloma and giant cell tumor; clinical and biochemical correlation is mandatory for definitive diagnosis.[4][8]

Molecular considerations

Recent identification of hotspot KRAS mutations in brown tumors has placed these lesions within the spectrum of RAS-MAPK–driven neoplasms, challenging the traditional view that they are purely reactive.[8] This finding does not currently alter clinical management but may have future implications for classification.

Workup and referral

Diagnosis requires integration of clinical, radiographic, and biochemical findings. Essential laboratory studies include serum PTH (intact), calcium, phosphorus, alkaline phosphatase, creatinine, and vitamin D levels.[4][5] Referral to nephrology is indicated for all patients with suspected jaw manifestations of CKD-MBD. Biopsy of jaw lesions is warranted when the diagnosis is uncertain or when a neoplastic process cannot be excluded on clinical and biochemical grounds.[3][4]

Medical management

The primary treatment targets the underlying metabolic derangement:

• Phosphate control: dietary phosphorus restriction and phosphate binders.[7][23]
• Vitamin D supplementation: active vitamin D analogs (calcitriol or paricalcitol) to suppress PTH and improve calcium absorption.[7][23]
• Calcimimetics (cinacalcet): used to lower PTH in patients on dialysis, often in combination with vitamin D analogs.[7]
• Adequate dialysis: optimization of hemodialysis or peritoneal dialysis regimen.[4][7]

Osseous jaw changes, including brown tumors, may partially or completely regress with correction of the metabolic abnormality.[4][12][20]

Parathyroidectomy

Surgical parathyroidectomy is indicated when PTH remains persistently elevated (typically >800 pg/mL for >6 months) despite maximal medical therapy, particularly with concurrent hypercalcemia, hyperphosphatemia, progressive osteodystrophy, or vascular/soft-tissue calcification.[7] Options include subtotal parathyroidectomy and total parathyroidectomy with autotransplantation; the former carries higher recurrence risk, while the latter has greater risk of permanent hypocalcemia.[7] Postoperative hungry bone syndrome with profound hypocalcemia occurs in approximately 25% of dialysis patients and requires aggressive calcium and calcitriol supplementation.[7]

Local surgical management

Surgical resection of jaw lesions is generally not first-line and is reserved for lesions causing significant functional impairment (airway compromise, severe malocclusion, pathologic fracture) or those that fail to regress after metabolic correction.[4][24] Parathyroidectomy does not reverse established skeletal deformities in Sagliker syndrome.[10]

Prognosis

Prognosis depends on the severity and duration of CKD and the adequacy of metabolic control. Brown tumors carry a favorable prognosis when hyperparathyroidism is corrected, with documented lesion regression.[4][20] Diffuse osteitis fibrosa/Sagliker syndrome carries a more guarded prognosis; in one multicenter series, two of four patients with Sagliker syndrome died during follow-up.[4] Renal transplantation, when feasible, offers the most definitive correction of the underlying metabolic disturbance.[4][12]

Sagliker syndrome

This extreme phenotype of CKD-related secondary hyperparathyroidism features severe maxillary and mandibular deformity producing a characteristic "uglifying" facial appearance, short stature, dental anomalies, gingival hyperplasia, fingertip changes, hearing loss, and neuropsychiatric impairment.[10][11] It has been reported predominantly in patients from developing countries who received delayed or inadequate treatment.[11] Mutations in GNAS1, FGF23, and FGFR3 genes have been described in some patients, suggesting possible genetic susceptibility.[10] Parathyroidectomy controls the metabolic disturbance but does not reverse established craniofacial deformities; reconstructive surgery may be required.[10][11]

Dental management considerations

Patients with CKD-MBD are at increased risk for delayed healing, infection, and medication-related complications. Dental practitioners should:

• Confirm pulp vitality before initiating endodontic treatment in patients with CKD and periapical radiolucencies.[16]
• Coordinate with the patient's nephrology team before invasive dental procedures, particularly regarding anticoagulation during dialysis and bleeding risk.[5]
• Monitor for incidental soft-tissue and vascular calcifications on routine dental radiographs, which may warrant medical referral.[14][19]